Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
CL594-68020 targets Angiotensinogen/AGT in applications and shows reactivity with human, pig samples.
| Tested Reactivity | human, pig |
| Host / Isotype | Mouse / IgG2b |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | Angiotensinogen/AGT fusion protein Ag16658 相同性解析による交差性が予測される生物種 |
| Full Name | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
| Calculated molecular weight | 485 aa, 53 kDa |
| Observed molecular weight | 52 kDa |
| GenBank accession number | BC011519 |
| Gene Symbol | AGT |
| Gene ID (NCBI) | 183 |
| RRID | AB_2934793 |
| Conjugate | CoraLite®594 Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 588 nm / 604 nm |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P01019 |
| Storage Buffer | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
| Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Angiotensinogen is a precursor of angiotensin II (Ang II), is expressed and synthesized largely in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. It has a key role in mediating vascular constriction and regulating salt and fluid homeostasis. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene also have been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease.